Our Portfolio


Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.


Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.